AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: LIXIANA (Daiichi Sankyo) (lixiana.com)
LIXIANA® delivers a clinic-first digital presence that is nearly devoid of typical marketing bullshit. It leverages hard data, peer-reviewed citations, and rigorous trial parameters to build authority, though its technical SEO implementation lags behind its clinical sophistication.
Integrate Organization and Product structured data (JSON-LD) to technically validate the brand’s global footprint and edoxaban’s regulatory status. Replace the static text citations with outbound digital object identifier (DOI) links to the NEJM and J Thromb Haemost publications to provide immediate proof paths. Add a ‘Regulatory Status’ section explicitly listing EMA/FDA approval dates and numbers to satisfy missing_elements. Update trial summary sections with ClinicalTrials.gov identifiers (e.g., NCT00781391) to enhance technical transparency.
The site exhibits high information density, prioritizing clinical data over marketing adjectives. While headings like ‘simple and convenient once-daily dosing’ (H2) contain mild power words, they are immediately supported by specific dosing instructions (60 mg/30 mg) and trial results. The body substance ratio is exceptional, citing Hazard Ratios (HR 0.80), Confidence Intervals (95% CI, 0.71 to 0.91), and p-values (P<0.001) for major bleeding events.
Black hole nodes and terminal leaf pages distort your hierarchy and weaken retrieval. Run a full Internal Linking Architecture analysis to expose the structural gaps hidden inside your graph.
There is zero semantic drift between the homepage signal and sub-page substance. The homepage H1 ‘For your eligible patients with NVAF & VTE’ transitions seamlessly into granular study designs for both NVAF and VTE on subsequent pages. Sub-pages provide the exact evidence promised, such as the inclusion/exclusion criteria and primary efficacy endpoints expected by healthcare professionals.
Identify the current state and friction diagnosis of your specific business model. Generate your Executive SEO Strategy to quantify the financial or conversion cost of strategic misalignment.
The site avoids standard ‘trust theatre’ like unverified customer reviews, resulting in a review_count of 0. Instead, it utilizes high-authority proof paths through peer-reviewed citations, specifically referencing the New England Journal of Medicine (NEJM 2013). While the proof_links_count is 0 in the structured data, the body text is saturated with verifiable academic references.
The proof density is superior, with a ratio of approximately one verifiable clinical stat or reference for every two sentences of descriptive text. Across the 4 pages, there are over 10 distinct instances of specific trial results and methodological specifications, far exceeding the threshold for high-substance sites.
For a high volume editorial domain example, open the Search Engine Journal Semantic HTML audit. View the SEJ Semantic HTML Audit to see how template drift and structural noise impact AI chunking.
The value proposition is highly specific to edoxaban and cannot be easily transposed to a competitor without changing the clinical data. Cliché usage is minimal, though it uses ‘Official Site’ and ‘simple and convenient’ (matched in industry_jargon as generic). Boilerplate language is restricted to necessary legal terms of use and headquarters information, rather than empty ‘About Us’ fluff.
The primary authority gap is technical rather than substantive; the site lacks JSON-LD Organization or Person schema (schema_json: null), which is a missed opportunity for a global brand like Daiichi Sankyo. Although it references the ‘Hokusai-VTE Investigators’ and ‘Giugliano RP,’ these experts are not linked via Person schema or sameAs digital footprints within the site structure.
There is no disconnect between marketing claims and demonstrated results. Every claim regarding the reduction of major bleeding vs. warfarin is tied to a specific clinical trial (ENGAGE AF-TIMI 48 or Hokusai-VTE) with transparent data reporting. Performance claims are mathematical (e.g., 2.75% vs 3.43%) rather than anecdotal.
Medical Devices, Pharma & Biotech BS: LIXIANA (Daiichi Sankyo) (lixiana.com)
The content perfectly aligns with the Pharmaceutical and Biotech category, specifically focusing on anticoagulation therapy. The use of clinical trial nomenclature (ENGAGE AF-TIMI 48, Hokusai-VTE) and rigorous inclusion/exclusion criteria confirms its status as a professional healthcare resource.
A page with no inbound links is invisible to AI, no matter how strong the content is. Open the Internal Linking Framework Guide to learn how link driven relationships shape retrieval, authority, and entity grouping.
“The low score of 16 is driven by the extreme information density and total lack of semantic drift. The few points deducted originate from the aging nature of the primary trial evidence (2013 data being stale by May 2026 standards) and the technical absence of structured schema data to support the brand's authority.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 25, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at LIXIANA (Daiichi Sankyo) to view the most current version of their content and see directly what the company offers.